XML 59 R68.htm IDEA: XBRL DOCUMENT v2.4.0.8
Segment Information Segment Information (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Segment Reporting Information [Line Items]                      
Depreciation and amortization                 $ 1,445.6 $ 1,462.2 $ 1,373.6
Revenue 5,808.8 5,772.6 5,929.7 5,602.0 5,957.3 5,443.3 5,600.7 5,602.0 23,113.1 22,603.4 24,286.5
Long-Lived Assets 8,741.3       8,990.5       8,741.3 8,990.5 9,372.4
Asset impairment, restructuring, and other special charges (35.4) 0 (63.5) (21.7) (204.0) (53.3) 0 (23.8) (120.6) (281.1) (401.4)
Income before income taxes 909.9 1,513.4 1,514.9 1,951.1 1,012.4 1,874.7 1,185.7 1,335.3 5,889.3 5,408.2 5,349.5
Acquired in-process research and development (57.1) 0 0 0         (57.1) 0 (388.0)
Gain (Loss) on Contract Termination                 495.4 787.8 0
Accounts Receivable, Minimum [Member]
                     
Segment Reporting Information [Line Items]                      
Concentration Risk, Percentage                 9.00% 9.00% 9.00%
Accounts Receivable, Maximum [Member]
                     
Segment Reporting Information [Line Items]                      
Concentration Risk, Percentage                 18.00% 18.00% 18.00%
Customer Concentration Risk, Minimum [Member]
                     
Segment Reporting Information [Line Items]                      
Concentration Risk, Percentage                 10.00% 10.00% 10.00%
Customer Concentration Risk, Maximum [Member]
                     
Segment Reporting Information [Line Items]                      
Concentration Risk, Percentage                 19.00% 19.00% 19.00%
United States [Member]
                     
Segment Reporting Information [Line Items]                      
Revenue                 12,889.7 12,313.1 12,977.2
Long-Lived Assets 4,649.6       5,064.7       4,649.6 5,064.7 5,485.3
Europe [Member]
                     
Segment Reporting Information [Line Items]                      
Revenue                 4,338.4 4,259.7 5,290.9
Long-Lived Assets 2,469.7       2,281.1       2,469.7 2,281.1 2,220.2
Japan [Member]
                     
Segment Reporting Information [Line Items]                      
Revenue                 2,063.8 2,246.2 2,104.1
Long-Lived Assets 81.1       101.5       81.1 101.5 102.9
Other Foreign Countries [Member]
                     
Segment Reporting Information [Line Items]                      
Revenue                 3,821.2 3,784.4 3,914.3
Long-Lived Assets 1,540.9       1,543.2       1,540.9 1,543.2 1,564.0
Total segment [Member]
                     
Segment Reporting Information [Line Items]                      
Income before income taxes                 5,571.6 4,901.5 6,138.9
Endocrinology [Member]
                     
Segment Reporting Information [Line Items]                      
Revenue                 7,304.4 6,810.9 6,806.7
Neuroscience [Member]
                     
Segment Reporting Information [Line Items]                      
Revenue                 7,216.2 7,575.1 9,723.8
Oncology [Member]
                     
Segment Reporting Information [Line Items]                      
Revenue                 3,268.5 3,281.6 3,322.2
Cardiovascular [Member]
                     
Segment Reporting Information [Line Items]                      
Revenue                 2,923.2 2,632.5 2,486.4
Other Pharmaceuticals [Member]
                     
Segment Reporting Information [Line Items]                      
Revenue                 249.3 266.8 268.8
Pharmaceutical Products Total [Member]
                     
Segment Reporting Information [Line Items]                      
Revenue                 20,961.6 20,566.9 22,607.9
Income before income taxes                 5,015.0 4,393.4 5,837.9
Animal Health Products [Member]
                     
Segment Reporting Information [Line Items]                      
Revenue                 2,151.5 2,036.5 1,678.6
Income before income taxes                 556.6 508.1 301.0
Human Pharmaceutical Products [Member]
                     
Segment Reporting Information [Line Items]                      
Depreciation and amortization                 1,350.0 1,370.0 1,300.0
Amylin [Member]
                     
Segment Reporting Information [Line Items]                      
Gain (Loss) on Contract Termination                 495.4 787.8 0
Animal Health Products [Member]
                     
Segment Reporting Information [Line Items]                      
Depreciation and amortization                 99.4 91.1 78.1
Cymbalta [Member] | United States [Member]
                     
Segment Reporting Information [Line Items]                      
Revenue                 $ 3,960.0